SCHEMBL4837392

SCHEMBL4837392

CC(C)N(C)CCCOc1ccc(C2(CN(C)C)CCOCC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SLC6A4 P31645 8/20 0.39
SLC6A3 Q01959 8/20 0.39
KDM4E B2RXH2 1/20 0.38
SLC6A2 P23975 4/20 0.37
HRH3 Q9Y5N1 3/20 0.37
POLB P06746 1/20 0.36
LSS P48449 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3277469 0.89 ALDH1A1 (0.49) ALDH1A1LMNAHTTSMN1; SMN2CYP1A2
SCHEMBL3270606 0.84 HRH3 (0.47) ALDH1A1LMNAHTTSMN1; SMN2CYP1A2
SCHEMBL3271437 0.84 LMNA (0.45) ALDH1A1LMNAHTTSMN1; SMN2CYP1A2
SCHEMBL3271881 0.82 HRH3 (0.47) ALDH1A1LMNAHTTSMN1; SMN2CYP1A2
SCHEMBL3271784 0.82 LMNA (0.48) ALDH1A1LMNAHTTSMN1; SMN2CYP1A2
SCHEMBL4837404 0.81 LMNA (0.40) ALDH1A1LMNAHTTSMN1; SMN2CYP1A2
SCHEMBL6268130 0.81 ALDH1A1 (0.42) ALDH1A1LMNAHTTSMN1; SMN2CYP1A2
SCHEMBL3272359 0.80 ALDH1A1 (0.43) ALDH1A1LMNAHTTSMN1; SMN2CYP1A2
SCHEMBL3275252 0.79 HRH3 (0.59) ALDH1A1LMNACYP1A2HRH3
SCHEMBL3270444 0.79 HRH3 (0.60) ALDH1A1LMNACYP1A2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1747210-B1 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS WARNER LAMBERT CO (US) 2010-06-30 EP disclosed
US-7456164-B2 Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable PFIZER, INC (US) 2008-11-25 US disclosed
US-7456164-B2 Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable PFIZER, INC (US) 2008-11-25 US disclosed
US-7456164-B2 Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable PFIZER, INC (US) 2008-11-25 US disclosed
US-20050267095-A1 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands ZIARCO INC. 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267095-A1 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands HRH4, HRH3, TLR4 ALDH1A1 832/4885LMNA 4730/4885HTT 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.